Bizily Scott
SEC CIK 1920738 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| FDMT | 4D Molecular Therapeutics, Inc. | Chief Legal, HR Off | 10.3K | — | $1.91M | 58 | 2022-12-01 | 2026-09-16 |
Most active insiders at FDMT, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Kirn David | See Remarks, Dir | — | $4.26M |
| 2 | Bizily Scott | CLO | — | $387.7K |
| 3 | Gupta Ashoo | VP, Fin, Ctrl | — | $6,734 |
| 4 | THEUER CHARLES | Dir | — | — |
Transactions 58
Purchase Sale Sale after option exercise All abbreviations
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DT | 2026-09-22 18:43 | 2026-09-16 | FDMT | 4D Molecular Therapeutics, Inc. | Bizily Scott | CLO | M - OptEx | $4.14 | +1,635 | 10.3K | +19% | +$6,769 |
| DT | 2026-09-22 18:43 | 2026-09-16 | FDMT | 4D Molecular Therapeutics, Inc. | Bizily Scott | CLO | S - Sale+OE | $13.65 | -1,635 | 8,617 | -16% | -$22.3K |
| DT | 2026-09-03 18:55 | 2026-09-01 | FDMT | 4D Molecular Therapeutics, Inc. | Bizily Scott | CLO | M - OptEx | $6.49 | +584 | 9,201 | +7% | +$3,790 |
| DT | 2026-09-03 18:55 | 2026-09-01 | FDMT | 4D Molecular Therapeutics, Inc. | Bizily Scott | CLO | S - Sale+OE | $14.00 | -584 | 8,617 | -6% | -$8,176 |
| DMT | 2026-08-17 17:34 | 2026-08-13+ | FDMT | 4D Molecular Therapeutics, Inc. | Bizily Scott | CLO | M - OptEx | $4.14 | +3,270 | 10.3K | +47% | +$13.5K |
| DMT | 2026-08-17 17:34 | 2026-08-13+ | FDMT | 4D Molecular Therapeutics, Inc. | Bizily Scott | CLO | S - Sale+OE | $12.10 | -3,270 | 8,617 | -28% | -$39.6K |
| DMT | 2026-07-02 16:07 | 2026-06-30 | FDMT | 4D Molecular Therapeutics, Inc. | Bizily Scott | CLO | M - OptEx | $6.20 | +6,566 | 15.2K | +76% | +$40.7K |
| DT | 2026-07-02 16:07 | 2026-06-30 | FDMT | 4D Molecular Therapeutics, Inc. | Bizily Scott | CLO | S - Sale+OE | $14.00 | -6,566 | 8,617 | -43% | -$91.9K |
| DT | 2026-06-25 16:38 | 2026-06-23 | FDMT | 4D Molecular Therapeutics, Inc. | Bizily Scott | CLO | M - OptEx | $4.14 | +9,810 | 18.4K | +114% | +$40.6K |
| DT | 2026-06-25 16:38 | 2026-06-23 | FDMT | 4D Molecular Therapeutics, Inc. | Bizily Scott | CLO | S - Sale+OE | $12.00 | -9,810 | 8,617 | -53% | -$117.7K |
| DT | 2025-12-19 | 2025-12-16 | FDMT | 4D Molecular Therapeutics, Inc. | Bizily Scott | CLO | M - OptEx | $4.14 | +1,635 | 5,229 | +45% | +$6,769 |
| DT | 2025-12-19 | 2025-12-16 | FDMT | 4D Molecular Therapeutics, Inc. | Bizily Scott | CLO | S - Sale+OE | $10.90 | -1,635 | 3,594 | -31% | -$17.8K |
| DT | 2025-11-19 | 2025-11-17 | FDMT | 4D Molecular Therapeutics, Inc. | Bizily Scott | CLO | M - OptEx | $4.14 | +1,635 | 5,229 | +45% | +$6,769 |
| DT | 2025-11-19 | 2025-11-17 | FDMT | 4D Molecular Therapeutics, Inc. | Bizily Scott | CLO | S - Sale+OE | $10.59 | -1,635 | 3,594 | -31% | -$17.3K |
| DT | 2025-10-27 | 2025-10-24 | FDMT | 4D Molecular Therapeutics, Inc. | Bizily Scott | CLO | M - OptEx | $6.49 | +1,084 | 6,272 | +21% | +$7,035 |
| DT | 2025-10-27 | 2025-10-24 | FDMT | 4D Molecular Therapeutics, Inc. | Bizily Scott | CLO | S - Sale+OE | $12.00 | -2,678 | 3,594 | -43% | -$32.1K |
| DT | 2025-10-20 | 2025-10-16 | FDMT | 4D Molecular Therapeutics, Inc. | Bizily Scott | CLO | M - OptEx | $4.14 | +1,635 | 6,823 | +32% | +$6,769 |
| DT | 2025-10-20 | 2025-10-16 | FDMT | 4D Molecular Therapeutics, Inc. | Bizily Scott | CLO | S - Sale+OE | $10.17 | -1,635 | 5,188 | -24% | -$16.6K |
| T | 2025-10-14 | 2025-10-09 | FDMT | 4D Molecular Therapeutics, Inc. | Bizily Scott | CLO | S - Sale | $10.00 | -2,408 | 5,188 | -32% | -$24.1K |
| T | 2025-09-26 | 2025-09-23 | FDMT | 4D Molecular Therapeutics, Inc. | Bizily Scott | CLO | S - Sale | $8.00 | -2,407 | 7,596 | -24% | -$19.3K |
| DT | 2024-09-18 | 2024-09-16 | FDMT | 4D Molecular Therapeutics, Inc. | Bizily Scott | CLO | S - Sale+OE | $16.33 | -500 | 6,781 | -7% | -$8,165 |
| DT | 2024-09-18 | 2024-09-16 | FDMT | 4D Molecular Therapeutics, Inc. | Bizily Scott | CLO | M - OptEx | $6.49 | +500 | 7,281 | +7% | +$3,245 |
| DT | 2024-08-21 | 2024-08-19 | FDMT | 4D Molecular Therapeutics, Inc. | Bizily Scott | CLO | M - OptEx | $6.49 | +500 | 7,281 | +7% | +$3,245 |
| DT | 2024-08-21 | 2024-08-19 | FDMT | 4D Molecular Therapeutics, Inc. | Bizily Scott | CLO | S - Sale+OE | $15.00 | -500 | 6,781 | -7% | -$7,500 |
| DT | 2024-07-18 | 2024-07-16 | FDMT | 4D Molecular Therapeutics, Inc. | Bizily Scott | CLO | S - Sale+OE | $27.11 | -1,750 | 6,781 | -21% | -$47.4K |
| DMT | 2024-07-18 | 2024-07-16 | FDMT | 4D Molecular Therapeutics, Inc. | Bizily Scott | CLO | M - OptEx | $7.60 | +1,750 | 7,281 | +32% | +$13.3K |
| DT | 2024-07-15 | 2024-07-11 | FDMT | 4D Molecular Therapeutics, Inc. | Bizily Scott | CLO | S - Sale+OE | $25.00 | -1,996 | 6,781 | -23% | -$49.9K |
| DT | 2024-07-15 | 2024-07-11 | FDMT | 4D Molecular Therapeutics, Inc. | Bizily Scott | CLO | M - OptEx | $15.78 | +1,996 | 8,777 | +29% | +$31.5K |
| DMT | 2024-07-03 | 2024-07-01 | FDMT | 4D Molecular Therapeutics, Inc. | Bizily Scott | CLO | M - OptEx | $7.55 | +4,248 | 5,985 | +245% | +$32.1K |
| DT | 2024-07-03 | 2024-07-01 | FDMT | 4D Molecular Therapeutics, Inc. | Bizily Scott | CLO | S - Sale+OE | $21.36 | -4,248 | 1,737 | -71% | -$90.7K |
| DT | 2024-06-20 | 2024-06-17 | FDMT | 4D Molecular Therapeutics, Inc. | Bizily Scott | CLO | S - Sale+OE | $23.71 | -1,750 | 1,737 | -50% | -$41.5K |
| DMT | 2024-06-20 | 2024-06-17 | FDMT | 4D Molecular Therapeutics, Inc. | Bizily Scott | CLO | M - OptEx | $7.60 | +1,750 | 3,487 | +101% | +$13.3K |
| DMT | 2024-05-20 | 2024-05-16 | FDMT | 4D Molecular Therapeutics, Inc. | Bizily Scott | CLO | S - Sale+OE | $25.45 | -1,750 | 1,737 | -50% | -$44.5K |
| DMT | 2024-05-20 | 2024-05-16 | FDMT | 4D Molecular Therapeutics, Inc. | Bizily Scott | CLO | M - OptEx | $7.60 | +1,750 | 2,237 | +359% | +$13.3K |
| DMT | 2024-04-18 | 2024-04-16 | FDMT | 4D Molecular Therapeutics, Inc. | Bizily Scott | CLO | M - OptEx | $7.60 | +1,750 | 3,487 | +101% | +$13.3K |
| DT | 2024-04-18 | 2024-04-16 | FDMT | 4D Molecular Therapeutics, Inc. | Bizily Scott | CLO | S - Sale+OE | $25.74 | -1,750 | 1,737 | -50% | -$45.0K |
| DMT | 2024-04-03 | 2024-04-01 | FDMT | 4D Molecular Therapeutics, Inc. | Bizily Scott | CLO | M - OptEx | $12.54 | +8,153 | 7,981 | New | +$102.2K |
| DT | 2024-04-03 | 2024-04-01 | FDMT | 4D Molecular Therapeutics, Inc. | Bizily Scott | CLO | S - Sale+OE | $31.78 | -8,153 | 1,737 | -82% | -$259.1K |
| DT | 2024-03-29 | 2024-03-27 | FDMT | 4D Molecular Therapeutics, Inc. | Bizily Scott | CLO | S - Sale+OE | $35.04 | -5,833 | 1,737 | -77% | -$204.4K |
| DMT | 2024-03-29 | 2024-03-27 | FDMT | 4D Molecular Therapeutics, Inc. | Bizily Scott | CLO | M - OptEx | $25.98 | +5,833 | 7,570 | +336% | +$151.5K |
| DMT | 2024-03-20 | 2024-03-18 | FDMT | 4D Molecular Therapeutics, Inc. | Bizily Scott | CLO | M - OptEx | $7.60 | +1,750 | 2,237 | +359% | +$13.3K |
| DT | 2024-03-20 | 2024-03-18 | FDMT | 4D Molecular Therapeutics, Inc. | Bizily Scott | CLO | S - Sale+OE | $31.27 | -1,750 | 1,737 | -50% | -$54.7K |
| DT | 2024-02-29 | 2024-02-27 | FDMT | 4D Molecular Therapeutics, Inc. | Bizily Scott | CLO | M - OptEx | $20.24 | +1,909 | 3,646 | +110% | +$38.6K |
| DT | 2024-02-29 | 2024-02-27 | FDMT | 4D Molecular Therapeutics, Inc. | Bizily Scott | CLO | S - Sale+OE | $30.00 | -1,909 | 1,737 | -52% | -$57.3K |
| DMT | 2024-02-21 | 2024-02-16 | FDMT | 4D Molecular Therapeutics, Inc. | Bizily Scott | CLO | M - OptEx | $7.60 | +1,750 | 3,487 | +101% | +$13.3K |
| DT | 2024-02-21 | 2024-02-16 | FDMT | 4D Molecular Therapeutics, Inc. | Bizily Scott | CLO | S - Sale+OE | $27.67 | -1,750 | 1,737 | -50% | -$48.4K |
| DMT | 2024-02-12 | 2024-02-08 | FDMT | 4D Molecular Therapeutics, Inc. | Bizily Scott | CLO | S - Sale+OE | $27.50 | -6,244 | 1,737 | -78% | -$171.7K |
| DMT | 2024-02-12 | 2024-02-08 | FDMT | 4D Molecular Therapeutics, Inc. | Bizily Scott | CLO | M - OptEx | $10.18 | +6,244 | 3,069 | New | +$63.6K |
| D | 2023-06-12 | 2023-06-08 | FDMT | 4D Molecular Therapeutics, Inc. | Bizily Scott | Chief Legal, HR Off | S - Sale+OE | $20.85 | -3,750 | 1,737 | -68% | -$78.2K |
| D | 2023-06-12 | 2023-06-08 | FDMT | 4D Molecular Therapeutics, Inc. | Bizily Scott | Chief Legal, HR Off | M - OptEx | $8.04 | +3,750 | 5,487 | +216% | +$30.1K |
| D | 2023-06-06 | 2023-06-01 | FDMT | 4D Molecular Therapeutics, Inc. | Bizily Scott | Chief Legal, HR Off | S - Sale+OE | $18.31 | -2,247 | 1,737 | -56% | -$41.1K |
| D | 2023-06-06 | 2023-06-01 | FDMT | 4D Molecular Therapeutics, Inc. | Bizily Scott | Chief Legal, HR Off | M - OptEx | $6.49 | +1,875 | 3,984 | +89% | +$12.2K |
| DT | 2023-04-25 | 2023-04-21 | FDMT | 4D Molecular Therapeutics, Inc. | Bizily Scott | Chief Legal, HR Off | S - Sale+OE | $20.00 | -3,750 | 2,109 | -64% | -$75.0K |
| DT | 2023-04-25 | 2023-04-21 | FDMT | 4D Molecular Therapeutics, Inc. | Bizily Scott | Chief Legal, HR Off | M - OptEx | $8.04 | +3,750 | 5,859 | +178% | +$30.1K |
| D | 2023-03-03 | 2023-03-01 | FDMT | 4D Molecular Therapeutics, Inc. | Bizily Scott | Chief Legal, HR Off | M - OptEx | $6.49 | +1,875 | 4,357 | +76% | +$12.2K |
| D | 2023-03-03 | 2023-03-01 | FDMT | 4D Molecular Therapeutics, Inc. | Bizily Scott | Chief Legal, HR Off | S - Sale+OE | $19.30 | -2,248 | 2,109 | -52% | -$43.4K |
| DM | 2022-12-05 | 2022-12-01 | FDMT | 4D Molecular Therapeutics, Inc. | Bizily Scott | Chief Legal, HR Off | S - Sale+OE | $22.79 | -6,000 | 4,332 | -58% | -$136.7K |
| DM | 2022-12-05 | 2022-12-01 | FDMT | 4D Molecular Therapeutics, Inc. | Bizily Scott | Chief Legal, HR Off | M - OptEx | $7.52 | +5,625 | 4,732 | New | +$42.3K |